ロード中...
CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers
Loss-of-function mutations in p16(INK4A) (CDKN2A) occur in approximately 80% of sporadic pancreatic ductal adenocarcinoma (PDAC), contributing to its early progression. While this loss activates the cell cycle-dependent kinases CDK4/6, which have been considered as drug targets for many years, p16(I...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4122288/ https://ncbi.nlm.nih.gov/pubmed/24986516 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-2923 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|